{
    "symbol": "ONTX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 23:14:04",
    "content": " Looking forward for narazaciclib, we expect the continued advancement of its phase 1 trials to allow for the second selection of a recommended phase 2 dose, which we anticipate having before the end of this year. With regards to Rigosertib, we plan to announce additional data in the phase 1/2 KRAS mutated my small cell lung cancer trial via an abstract submitted to the upcoming ESMO meeting in September. And thanks for taking my questions have given us sounds like you're on track to identify a potential recommended phase 2 dose for narazaciclib as early as the end of this year, and also looks like you're enrolling dose cohort five for both of the phase 1 study should we interpret that as potentially dose cohorts six to seven as being likely maximum tolerated doses."
}